Background illustration for clinical trials search

Triple Negative Breast Cancer Clinical Trials

Browse 2,256 triple negative breast cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1
Active & Responsive

Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)

for
Breast Cancer
Location: Columbus OH, Chicago IL, Iowa City IA
Sponsor: University of Illinois Chicago

Sex: All

Age: 18+

Code: NCT06169371

Phase 4, Recruiting
Active & Responsive

A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

for
Solid Tumor
Location: New York NY, Philadelphia PA, Washington D.C. DC,
Sponsor: Biohaven Therapeutics Ltd.

Sex: All

Age: 18+

Code: NCT06384807

Phase 1, Phase 2, Recruiting
Active & Responsive

Community Services Navigation to Advance Health Equity in Breast Cancer Screening

for
Breast Cancer
Location: Salt Lake City UT
Sponsor: University of Utah

Sex: All

Age: 18+

Code: NCT06305312

Recruiting
Active & Responsive

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

for
Cancer, PDAC - Pancreatic Ductal Adenocarcinoma,
Location: Boston MA, New York NY, Fairfax VA, Durham NC,
Sponsor: Alterome Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06835569

Phase 1, Recruiting
Active & Responsive

A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases

for
Solid Tumor Malignancies, Brain Metastases From Solid Tumors
Location: Fairfax VA, Charleston SC, Detroit MI, Houston TX,
Sponsor: A2A Pharmaceuticals Inc.

Sex: All

Age: 18+

Code: NCT06136884

Phase 1, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & Responsive

F.L.O.S.S. Project (Facilitated Lessons on Oral and Systemic Health in Survivors)

for
Oral Mucositis, Periodontal Diseases, Cancer
Location: Washington D.C. DC
Sponsor: Georgetown University

Sex: All

Age: 25 - 70+

Code: NCT06315855

Recruiting
Active & Responsive

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

for
Autoimmune Disease, Crohn Disease, Dermatomyositis,
Location: Boston MA, New Haven CT, Mineola NY, New York NY,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT03816345

Phase 1, Recruiting
Active & Responsive

Decentralized Clinical Trial of Effectiveness of EnergyPoints App in Cancer Survivors

for
Cancer-related Problem/Condition, Fatigue in Cancer Survivors,
Location: New York NY
Sponsor: 5 Point App, Inc.

Sex: All

Age: 18+

Code: NCT06754722

Recruiting
Active & Responsive

Liposomal Bupivacaine in Benign Soft Tissue Tumor Resection

for
Benign Neoplasm
Location: Corvallis OR
Sponsor: Samaritan Health Services

Sex: All

Age: 18+

Code: NCT05082441

Recruiting
Active & Responsive

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

for
PIK3CA Mutation, HER2- Negative Breast Cancer,
Location: Boston MA, New Haven CT, New York NY, Hackensack NJ,
Sponsor: Relay Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06982521

Phase 3, Recruiting
Active & Responsive

Increasing Germline Genetic Testing for Patients With Cancer

for
Hereditary Pancreatic Cancer, Conditions or Focus of Study,
Location: Danville PA, Durham NC, Salisbury NC, Orlando FL,
Sponsor: Josh Peterson

Sex: All

Age: 0+

Code: NCT07307664

Recruiting
Active & Responsive

Rutgers University Study of the Genetics of Breast Cancer.

for
Breast Cancer Risk, Breast Cancer Prevention, Breast Cancer
Location: Piscataway NJ
Sponsor: Rutgers, The State University of New Jersey

Sex: All

Age: 18+

Code: NCT06773897

Recruiting
Active & Responsive

Women Informed to Screen Depending on Measures of Risk (Wisdom Study)

for
Breast Cancer Screening, Breast Carcinoma in Situ,
Location: New York NY, Miami FL, Birmingham AL, Chicago IL,
Sponsor: University of California, San Francisco

Sex: Female

Age: 30 - 70+

Code: NCT02620852

Recruiting
Active & Responsive

2910 nm Erbium-Doped Fluoride Fiber Glass Laser for the Treatment of Advanced Perioral Lines and Wrinkles

for
Photodamaged Skin, Rhytids, Lines Skin, Wrinkles and Rhytides
Location: Houston TX
Sponsor: FA Corporation

Sex: All

Age: 50 - 70+

Code: NCT07222397

Recruiting
Active & Responsive

Caris Biorepository Research Protocol

for
Cancer, Early Detection of Cancer, Minimal Residual Disease
Location: Ridge NY, Sparta NJ, Potsdam NY, Baltimore MD,
Sponsor: Caris Science, Inc.

Sex: All

Age: 18+

Code: NCT01499394

Recruiting
Active & Responsive

Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer

for
Miscellaneous Neoplasm, Nos, Non-Neoplastic Condition, Nos
Location: Rockport ME, Belfast ME, Damariscotta ME, Augusta ME,
Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 18+

Code: NCT07091617

Recruiting
Active & ResponsiveNew

A Study of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid Tumors

for
Solid Tumor
Location: Seattle WA
Sponsor: Coherus Oncology, Inc.

Sex: Male

Age: 18+

Code: NCT07945821

Phase 1, Phase 2, Recruiting
Active & ResponsiveNew

XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors

for
Metastatic NSCLC - Non-Small Cell Lung Cancer,
Location: Fairfax VA, Canton OH, Fort Worth TX
Sponsor: Xilio Development, Inc.

Sex: All

Age: 18+

Code: NCT07688577

Phase 1, Phase 2, Recruiting
Active & ResponsiveNew

A Study of DS-3939a in Participants With Solid Tumors

for
Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer,
Location: Fairfax VA, Fayetteville AR
Sponsor: Daiichi Sankyo

Sex: All

Age: 18+

Code: NCT07739966

Phase 1, Phase 2, Recruiting
Active & ResponsiveNew

Decision Support for Chemoprevention

for
Breast Cancer
Location: New York NY
Sponsor: Columbia University

Sex: Female

Age: 40 - 70+

Code: NCT07899151

Recruiting

What is triple negative breast cancer?

Triple negative breast cancer, or TNBC, is breast cancer whose cells test negative for estrogen receptors, progesterone receptors, and excess HER2 protein, so hormone therapy and HER2 targeted drugs do not work against it. It tends to grow faster and is more common in women who have not gone through menopause, in Black women, and in people with an inherited BRCA1 mutation, so genetic testing is recommended for everyone diagnosed. In US data, five year relative survival is about 92 percent when it is found while localized, 67 percent with regional spread, and 15 percent once it has reached distant organs. Standard treatment for early stage disease is chemotherapy combined with immunotherapy before surgery, followed by more treatment after; metastatic disease is treated with chemotherapy, immunotherapy for PD-L1 positive tumors, and antibody drug conjugates. Other breast cancers are covered on our breast cancer clinical trials page.

Types of triple negative breast cancer clinical trials

Who can participate in triple negative breast cancer clinical trials?

Is triple negative breast cancer hereditary?

Stages of triple negative breast cancer, and why they matter for trials

How to enroll in a triple negative breast cancer clinical trial